docetaxel anhydrous has been researched along with abt-510 in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (abt-510) | Trials (abt-510) | Recent Studies (post-2010) (abt-510) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 28 | 10 | 4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Emmenegger, U; Henkin, J; Kerbel, RS; McKay, LM; Veliceasa, D; Volpert, OV; Yap, R | 1 |
1 other study(ies) available for docetaxel anhydrous and abt-510
| Article | Year |
|---|---|
Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Cell Line; Cell Line, Tumor; Cisplatin; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Endothelial Cells; Fas Ligand Protein; fas Receptor; Flow Cytometry; Humans; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Oligopeptides; Platelet Endothelial Cell Adhesion Molecule-1; Taxoids; Thrombospondins; Xenograft Model Antitumor Assays | 2005 |